Compare Star Bulk Carriers Corp (SBLK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs 10X Genomics Inc — how do they compare? Star Bulk Carriers Corp trades at $26.59 (market cap $2.91B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 3.95% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SBLK | TXG | |
|---|---|---|
Market Cap | $2.91B | $5.48B |
Sector | Industrials | Health |
52-Week High | $28.21 | $45.80 |
52-Week Low | $16.79 | $11.34 |
Enterprise Value | $3.61B | $5.02B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $26.09, up 4.78% in the last session, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in Q4 2025 and Q1 2026, with Q2 2026 EPS expected at $0.96. Financials show improving profitability, with a net income margin of 13.01% in 2026, and a dividend of $0.50 paid in June 2026. Analyst consensus is bullish, with 14 buys out of 24 ratings.
SBLK's outlook is supported by robust free cash flow and a healthier balance sheet, but risks include spot rate volatility and broader market pressures. The stock offers potential for high dividend yields and earnings growth, though investor caution is warranted amid sector cyclicality and economic uncertainties.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
